Atossa Therapeutics/ATOS

$1.32

-
-
1D1W1MYTD1YMAX

About Atossa Therapeutics

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing medicines in areas of significant unmet medical need in oncology with a focus on using (Z)-endoxifen to prevent and treat breast cancer. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. It is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. It has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).

Ticker

ATOS

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Steven Quay

Employees

10

Headquarters

Seattle, United States

ATOS Metrics

BasicAdvanced
$179M
Market cap
-
P/E ratio
-$0.24
EPS
1.20
Beta
-
Dividend rate
$179M
1.20265
$2.31
$0.62
2M
16.339
-28.65%
-29.93%
-29.84%
2.078
2.082
-4.99%

What the Analysts think about ATOS

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
303.79% upside
High $6.00
Low $4.00
$1.32
Current price
$5.33
Average price target

ATOS Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$5.8M
-24.68%
Profit margin
0%
NaN%

ATOS Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 25%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.08
-$0.05
-$0.09
-$0.05
-
Expected
-$0.06
-$0.07
-$0.06
-$0.07
-$0.06
Surprise
33.33%
-28.57%
58.82%
-25%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Atossa Therapeutics stock?

Atossa Therapeutics (ATOS) has a market cap of $179M as of May 30, 2024.

What is the P/E ratio for Atossa Therapeutics stock?

The price to earnings (P/E) ratio for Atossa Therapeutics (ATOS) stock is 0 as of May 30, 2024.

Does Atossa Therapeutics stock pay dividends?

No, Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders as of May 30, 2024.

When is the next Atossa Therapeutics dividend payment date?

Atossa Therapeutics (ATOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Atossa Therapeutics?

Atossa Therapeutics (ATOS) has a beta rating of 1.2. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Atossa Therapeutics stock price target?

The target price for Atossa Therapeutics (ATOS) stock is $5.33, which is 303.79% above the current price of $1.32. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Atossa Therapeutics stock

Buy or sell Atossa Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing